Becker's Healthcare March 5, 2024
Drugmakers that were selected in early February to begin price negotiations for 10 of the most expensive drugs in the U.S. as part of the Biden administration’s Inflation Reduction Act have sent the federal government counteroffers, President Joe Biden confirmed in a March 4 update.
In August 2023, HHS announced the 10 drugs in the first round of negotiations — which in total cost Medicare enrollees $3.4 billion in out-of-pocket costs in 2022 alone.
The 10 drugs included in the first round of negotiations were: Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara and Fiasp (as well as related Fiasp varieties).
Drugmakers had one month to accept or propose counteroffers, which President Biden confirmed March 4 had been...
Today's Sponsors
Today's Sponsor